Molecular and Clinical Hematology Branch (MCHB)
Griffin Rodgers, M.D., Chief
John Fitzgerald Tisdale, M.D.
Formed in 1998, the Molecular and Clinical Hematology Branch is administratively managed by NIH’s National Heart, Lung, and Blood Institute. The branch research interests include:
- Planning and conducting basic and clinical research on selected inherited and acquired diseases of human blood, utilizing contemporary biochemical, molecular, and physiological techniques;
- Developing and validating models, including cellular and transgenic systems, to permit the delineation of regulatory mechanisms in normal and pathological hematopoiesis and to facilitate pharmacological or molecular genetic approaches to correct or compensate for abnormalities associated with disease states; and
- Expediting the translation of novel basic scientific discovery to the appropriate level of preclinical or clinical investigation.
Molecular Hematology Section
The research interests of this section include:
- Planning and conducting investigations on the molecular and cellular bases of selected congenital and acquired hematological disorders;
- Developing quantitative methods to express disease severity or activity, amenable to sequential applications;
- Studying gene expression and differentiation in erythroid cells in normal and pathological hematopoietic states;
- Studying the molecular basis of lineage-specific differentiation of hematopoietic stem cells; and
- Developing therapies for hemoglobinopathies and other genetic blood disorders based on the modification of target gene expression.
Page last updated: June 21, 2013